SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as it faces a wave of analyst downgrades and intense investor frustration over its prolonged stock underperformance, despite a low valuation and active share buyback program. While many criticize current management and see it as 'dead money,' a bullish segment argues the fintech giant is significantly undervalued, poised for a rebound as it solidifies its position in digital payments and the evolving 'buy now, pay later' market.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd (SUGP) is trending as community discussion highlights its ultra-low share float and significant short interest, creating strong speculation for a potential short squeeze. Traders are actively drawing comparisons to past high-volatility runners like SMX, fueled by its presence on the Reg SHO list, high cost to borrow, and anticipation of upcoming earnings and contract news as potential catalysts.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is trending after announcing preliminary quarterly and full-year results that significantly beat revenue expectations, sparking strong bullish sentiment across the community. Investors are keenly discussing the impressive growth, coupled with high analyst price targets and the potential for a rally driven by the stock's low free float. However, some continue to voice concerns regarding the company's cash reserves and the ongoing risk of dilution.

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Atara Biotherapeutics (ATRA) is trending following a second FDA Complete Response Letter for its EBVALLO cancer therapy, which now cites concerns over clinical trial design despite previously resolved manufacturing issues. The community is expressing significant frustration over the FDA's unexpected change in position and questioning the need for a new trial, especially given the drug's existing approval in Europe.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is actively trending as its advanced agentic and voice AI technology showcased at a recent major tech conference generated significant buzz, leading to new partnerships in the automotive and robotics sectors. The community is heavily discussing the stock's high short interest, anticipating a potential squeeze, and highlighting its strong revenue growth and strategic position within the expanding AI market.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony is trending amidst escalating geopolitical tensions, particularly concerning critical minerals and China's tightening export restrictions, positioning the company as a crucial domestic supplier for defense. The community is actively discussing its role as the sole North American integrated antimony producer for the U.S. military and anticipating significant government investment to secure national supply chains. Sentiment remains highly bullish, with many seeing the company as undervalued given its strategic importance and expected contract expansions.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is generating significant buzz as investors anticipate a major re-rating for Chinese tech, driven by the company's accelerating AI and cloud growth and strategic investments in startups like MiniMax. The community is actively discussing a potential technical breakout and short squeeze, fueled by the belief that the stock is deeply undervalued and poised for substantial upside as the narrative shifts towards China's AI dominance.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending following recent developments, including Amazon Pharmacy's launch of Novo Nordisk's oral GLP-1 weight loss pill which is notably unavailable on HIMS's platform, compounded by an analyst downgrade citing elevated 2026 investment outlook. This has ignited a split in community sentiment, with many questioning HIMS's competitive moat, while others actively buy the dip, asserting confidence in the company's broader personalized healthcare platform and vertical integration for long-term growth.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending amidst a significant multi-year, nine-figure agreement with the Swedish Armed Forces, underscoring its robust demand for satellite services and fueling community excitement. Investors are actively discussing the company's growing backlog and strategic collaborations, such as 'Project Suncatcher' with Google for AI-enabled space data, as the broader space sector experiences accelerating momentum.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax (ABVX) is trending due to heightened speculation surrounding a potential takeover by Eli Lilly and other major pharmaceutical companies, with reports from French media and government sources fueling the buzz. The community is actively discussing an impending bidding war and significant premiums for its promising ulcerative colitis drug, obefazimod, which has demonstrated strong Phase 3 data. This innovative treatment positions Abivax as a highly attractive target in the competitive inflammatory bowel disease market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

WAVE Life Sciences (NASDAQ:WVE) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised WAVE Life Sciences from a "sell" rating to a "hold" rating in a report on Sunday...

WAVE Life Sciences (NASDAQ:WVE) Shares Down 4.5% - Here's Why

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 4.5% - Here's What Happened...

Chris Francis Sells 9,375 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) insider Chris Francis sold 9,375 shares of WAVE Life Sciences stock in a transaction that occurred on Friday, January 2nd. The stock was sold at...

WAVE Life Sciences (NASDAQ:WVE) Insider Sells $150,281.25 in Stock

WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) insider Chris Francis sold 9,375 shares of the firm's stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an...

WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - What's Next?

WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Still a Buy...

Three Genomics Stocks Worth Tracking This Year 

Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.

WAVE Life Sciences (NASDAQ:WVE) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered WAVE Life Sciences from a "hold" rating to a "sell" rating in a research note on Saturday...

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 7.1% - Here's What Happened

WAVE Life Sciences (NASDAQ:WVE) Trading Down 7.1% - What's Next...

Moody Aldrich Partners LLC Lowers Stock Holdings in WAVE Life Sciences Ltd. $WVE

Moody Aldrich Partners LLC lowered its holdings in WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 16.9% during the 3rd quarter, according to the company in its most recent filing with the...

Voya Investment Management LLC Raises Stock Position in WAVE Life Sciences Ltd. $WVE

Voya Investment Management LLC boosted its position in shares of WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 736.5% in the third quarter, according to its most recent Form 13F filing with...

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$13.85
Prev Close	$13.84
Open	$13.97
Dividend Yield	N/A
50-Day Moving Average	$11.80
Beta	1.38
Avg. Volume	12.68M
PE Ratio	-18.52

52-Week High	$21.73
52-Week Low	$5.28
Market Capitalization	$2.71B
EPS (Annual)	-$0.7015
Price to Book	17.81
Revenue Per Employee	$376,048.61
Enterprise Value/EBITDA	N/A

WVE
Wave Life Sciences Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest WVE News

WVEWave Life Sciences Ltd